Skip to content

Eculizumab fixed PK and authored response diagnostics

Three fixed eculizumab PK vectors with apparent distribution, exposure accounting and explicitly authored algebraic C5 and hemolysis diagnostics.

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis ↗

Frontiers in Neurology

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How do reference and exploratory clearance contexts change accumulation?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Marginal-mean PK coefficient vector

Specified constant PK vector and fixed authored response diagnostics on the complete supplied 16-infusion calendar; no individual or original fitted-population interpretation.

0–4,368.58 hour

Scenario details

Marginal-mean PK coefficient vector

Specified constant PK vector and fixed authored response diagnostics on the complete supplied 16-infusion calendar; no individual or original fitted-population interpretation.

Readouts

Central conc · ug/mL
Apparent central serum eculizumab concentration
Exposure (AUC) · ug*hour/mL
AUC ug h mL
Accounted drug · mg
Cumulative delivered drug budget
Authored C5 diagnostic · ug/mL
Authored inhibitory C5 curve; not original fitted free-C5 prediction
Authored hemolysis diagnostic · dimensionless
Authored capped-linear percent hemolysis diagnostic; not the paper double-sigmoid fit

Study purpose

  • How do the model's key biological readouts change under marginal-mean pk coefficient vector?

Assumptions

  • Interpret patterns within this model and starting configuration; do not treat them as clinical predictions or treatment recommendations.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
h
h
4369 → 168

Time between reported samples.

h
24 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Biology

Three fixed eculizumab PK vectors with apparent distribution, exposure accounting and explicitly authored algebraic C5 and hemolysis diagnostics.

Three fixed eculizumab PK vectors with apparent distribution, exposure accounting and explicitly authored algebraic C5 and hemolysis diagnostics.

Model details

8 parameters · 5 states · 5 equations · 24 derived outputs

Classification & API access
Therapeutic
Eculizumab
Modality
Monoclonal antibody
Target
Complement C5
Disease / scope
Generalized myasthenia gravis
ParameterDefaultUnitDescription
Systemic clearanceCL_L_h0.0106L/hFixed supplied PK or authored diagnostic coordinate for the selected context; no editable, fitting or population domain.
Intercompartmental clearanceQ_L_h0.251L/hFixed supplied PK or authored diagnostic coordinate for the selected context; no editable, fitting or population domain.
Central distribution volumeV1_L2.54LFixed supplied PK or authored diagnostic coordinate for the selected context; no editable, fitting or population domain.
Peripheral distribution volumeV2_L2.73LFixed supplied PK or authored diagnostic coordinate for the selected context; no editable, fitting or population domain.
Authored zero drug C5 curve levelfree_c5_baseline_ug_mL125µg/mLFixed supplied PK or authored diagnostic coordinate for the selected context; no editable, fitting or population domain.
Authored C5 curve exponentfree_c5_hill4.399683027209326—Fixed supplied PK or authored diagnostic coordinate for the selected context; no editable, fitting or population domain.
Eculizumab concentration IC50 for free C5free_c5_ic50_ug_mL33.1µg/mLFixed supplied PK or authored diagnostic coordinate for the selected context; no editable, fitting or population domain.
Authored C5 scale for the 100 percent linear curvehemolysis_scale_ug_mL2.5µg/mLFixed supplied PK or authored diagnostic coordinate for the selected context; no editable, fitting or population domain.

Related models

SB12/eculizumab fixed-group PK/PD referenceRavulizumab PK and independent C5 decay coordinatesDupilumab exposure and atopic-dermatitis responsePertuzumab fixed serum PK contexts

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics